Oragenics (NYSE:OGEN) Coverage Initiated by Analysts at StockNews.com

Research analysts at StockNews.com started coverage on shares of Oragenics (NYSE:OGENGet Free Report) in a research report issued on Friday. The firm set a “sell” rating on the stock.

Oragenics Stock Up 12.5 %

NYSE:OGEN opened at $0.36 on Friday. Oragenics has a 52 week low of $0.25 and a 52 week high of $7.74. The firm has a 50 day moving average of $0.33 and a 200 day moving average of $0.92. The stock has a market capitalization of $4.40 million, a price-to-earnings ratio of -0.05 and a beta of 0.43.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Oragenics stock. Virtu Financial LLC purchased a new stake in shares of Oragenics, Inc. (NYSE:OGENFree Report) during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 22,675 shares of the company’s stock, valued at approximately $33,000. Virtu Financial LLC owned approximately 0.51% of Oragenics at the end of the most recent quarter. 18.71% of the stock is owned by institutional investors.

About Oragenics

(Get Free Report)

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.

Read More

Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.